Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.4348 -0.0110 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 484,249
Open 0.4660
Bid (Size) 0.4205 (5)
Ask (Size) 0.4326 (3)
Prev. Close 0.4458
Today's Range 0.4201 - 0.4660
52wk Range 0.3051 - 2.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement 
From Cognition Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-39.9%
-39.9%
1 Month
+25.3%
+25.3%
3 Month
-34.7%
-34.7%
6 Month
-8.3%
-8.3%
1 Year
-78.2%
-78.2%

More News

Read More
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference
Via News Direct
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Is Targeting A Critical Form Of Dementia
Via News Direct
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Via Benzinga
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?
Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?
The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market
What is the current price of Cognition Therapeutics, Inc. - Common Stock?
The current price of Cognition Therapeutics, Inc. - Common Stock is 0.4348
When was Cognition Therapeutics, Inc. - Common Stock last traded?
The last trade of Cognition Therapeutics, Inc. - Common Stock was at 05/05/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.